Filana Therapeutics, Inc. FLNA
NASDAQ
| 09/30/2026 | 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | 12.76M | 12.99M | 14.81M | 23.93M | 40.61M |
| Gross Profit | -12.76M | -12.99M | -14.81M | -23.93M | -40.61M |
| SG&A Expenses | 25.82M | 26.32M | 29.20M | 30.50M | 33.76M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 41.39M | 41.97M | 46.67M | 57.09M | 77.03M |
| Operating Income | -41.39M | -41.97M | -46.67M | -57.09M | -77.03M |
| Income Before Tax | -42.20M | -42.28M | -77.90M | -90.97M | -106.03M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -42.20 | -42.28 | -77.90 | -90.97 | -106.03 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -42.20M | -42.28M | -77.90M | -90.97M | -106.03M |
| EBIT | -41.39M | -41.97M | -46.67M | -57.09M | -77.03M |
| EBITDA | -40.32M | -40.99M | -45.71M | -56.15M | -76.20M |
| EPS Basic | -0.87 | -0.88 | -1.61 | -1.88 | -2.20 |
| Normalized Basic EPS | -0.49 | -0.50 | -0.55 | -0.68 | -0.93 |
| EPS Diluted | -0.88 | -0.88 | -1.62 | -1.89 | -2.20 |
| Normalized Diluted EPS | -0.49 | -0.50 | -0.55 | -0.68 | -0.93 |
| Average Basic Shares Outstanding | 193.39M | 193.23M | 193.23M | 193.19M | 192.98M |
| Average Diluted Shares Outstanding | 193.39M | 193.23M | 193.23M | 193.19M | 192.98M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |